Please use this identifier to cite or link to this item: https://doi.org/10.1038/sj.bjp.0707165
Title: Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents
Authors: Lin, H.-S. 
Hu, C.-Y.
Chan, H.-Y.
Liew, Y.-Y.
Huang, H.-P.
Lepescheux, L.
Bastianelli, E.
Baron, R.
Rawadi, G.
Clément-Lacroix, P.
Keywords: Histone deacetylase inhibitor
MS-275
Rheumatoid arthritis
Suberoylanilide hydroxamic acid
Issue Date: Apr-2007
Source: Lin, H.-S., Hu, C.-Y., Chan, H.-Y., Liew, Y.-Y., Huang, H.-P., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G., Clément-Lacroix, P. (2007-04). Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. British Journal of Pharmacology 150 (7) : 862-872. ScholarBank@NUS Repository. https://doi.org/10.1038/sj.bjp.0707165
Abstract: Background and purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Histone deacetylase inhibitors (HDACi), a new class of anti-cancer agents, have recently been reported to exhibit potent anti-inflammatory activities. A proof of concept study was carried out with suberoylanilide hydroxamic acid (SAHA) and MS-275, two HDACi currently undergoing clinical investigations for various oncological indications. Experimental approach: The anti-rheumatic effects of SAHA and MS-275 were assessed in both mouse and rat collagen induced arthritis (CIA) models. Key results: SAHA exhibited moderate prophylactic efficacy. It attenuated paw swelling due to inflammation, decreased bone erosion in both mice and rats and reduced slightly the RA-induced bone resorption in rats. However, SAHA could not inhibit the onset of arthritis. In contrast, MS-275 displayed dramatic anti-rheumatic activities. In prophylactic intervention, high doses of MS-275 prevented bone erosion and markedly delayed the onset of arthritis; at low doses, MS-275 strongly attenuated paw swelling, bone erosion, and bone resorption associated with RA. Furthermore, the therapeutic efficacy of MS-275 was also documented. After the onset of arthritis, it could stop the disease progression and joint destruction.. An anti inflammatory effect of MS-275 was also confirmed through its capacity to decrease serum IL-6 and IL-1β levels in the CIA induced mouse model. The anti-rheumatic activity of MS-275 was also confirmed through histological observation. No synovial hyperplasia, pannus formation, cartilage or bone destruction were observed in the high dose prophylactic intervention in mice. Conclusion and implication: This study strongly supported HDACi as an innovative therapeutic strategy for RA. © 2007 Nature Publishing Group All rights reserved.
Source Title: British Journal of Pharmacology
URI: http://scholarbank.nus.edu.sg/handle/10635/105665
ISSN: 00071188
DOI: 10.1038/sj.bjp.0707165
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

186
checked on Feb 22, 2018

WEB OF SCIENCETM
Citations

164
checked on Jan 17, 2018

Page view(s)

30
checked on Feb 19, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.